| Name | Title | Contact Details |
|---|
Softtek is the leading Near Shore service provider for North America, as well as Latin America's largest private IT service provider.
WHAT WE DO. We are coding security professionals with varying backgrounds in writing code, assessing application security, and advising the most security minded organizations in the world. We know how to break things, and we can help make
With Verisma® services and technology, health information managers elevate their organization`s method of securely disclosing confidential information to patients, attorneys, and other third parties. Built on the principles of truth and accuracy, Verisma is a trusted partner in complying with changing regulations while reducing errors, turnaround time, and cost. Verisma HITRUST® certified technology integrates with existing EHRs and portals for advanced automation and transparency uniquely designed for release of information (ROI), self-serve request tracking, and audits. Flexible service models including full-service, technology-only, or a hybrid seamlessly blend Verisma`s end-to-end solution with the needs of existing staff. Our partnership is truly a promise to put patient protection first.
TrueAbility was founded to give technical professionals a platform to prove their skills, and to make it easier for companies to find, assess, and hire technical talent. The founders collectively hired over 1100 system administrators, network administrators, developers, and other technical employees during their careers at a leading global technology company. Frustration with the technical recruiting process led to the creation of TrueAbility.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.